Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03822208 · ClinicalTrials.gov registry record · Phase 1
First in Human Study for Safety and Tolerability of AL003.
A Phase 1 study, sponsored by Alector.
- Completed
- Registry status
- Phase 1
- Development phase
- 54
- Enrollment target
NCT03822208 is a Phase 1 study that has completed, run by Alector. The registered enrollment target is 54 participants.
The verdict
NCT03822208, a Phase 1 study, has completed, sponsored by Alector.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 54 participants
- Enrollment target
Study Summary
This is a multi-center, randomized, double-blind, placebo-controlled, dose escalation first in human (FIH) study in healthy adults and in patients with mild to moderate Alzheimer's disease. The study is designed to systematically assess the safety (including immunogenicity) and tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of AL003.
Interventions
- OTHER Saline Solution
- BIOLOGICAL AL003
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 54 participants |
| Start Date | 2019-03-29 |
| Est. Completion | 2021-05-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03822208
The ClinicalTrials.gov registry entry for NCT03822208 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 54 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alector, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Saline Solution is the first listed.
NCT03822208 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03822208 about?
NCT03822208 is a clinical study titled "First in Human Study for Safety and Tolerability of AL003.". This is a multi-center, randomized, double-blind, placebo-controlled, dose escalation first in human (FIH) study in healthy adults and in patients with mild to moderate Alzheimer's disease. The study is designed to systematically assess the safety (including immunogenicity) and tolerability, pharmac...
What is the current status of trial NCT03822208?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 54 participants. The study started on 2019-03-29. Estimated completion is 2021-05-06.
What interventions are being tested in trial NCT03822208?
The interventions under investigation include: Saline Solution (OTHER), AL003 (BIOLOGICAL).
Who is sponsoring clinical trial NCT03822208?
This trial is sponsored by Alector, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.